Lumakras | search
Click here to view Lumakras news from 60+ newspapers.
Bookmark or Share- LUMAKRAS® (sotorasib) - Non-Small Cell Lung Cancer (NSCLC) TreatmentLUMAKRAS ® is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor has an abnormal KRAS G12C gene, and who have received at least one prior treatment for their cancer.
- Sotorasib is First KRAS Inhibitor Approved by FDA - NCIFDA has approved the first KRAS-blocking drug, called sotorasib (Lumakras). The approval, which covers the use of sotorasib for some patients with advanced lung cancer, was based on the results of the CodeBreak100 trial.
- Lumakras: Uses, Dosage, Side Effects, Warnings - Drugs.comLumakras (sotorasib) is for the treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Includes Lumakras side effects, interactions and indications.
- LUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR ... - AmgenLUMAKRAS is the only KRAS G12C inhibitor approved anywhere in the world with approval in 44 markets, including the United States, the European Union, the United Kingdrom and Japan. CodeBreaK 200 is the first randomized, controlled clinical trial for a KRAS G12C inhibitor.
- FDA Approves LUMAKRAS™ (Sotorasib), The First And Only ... - AmgenLUMAKRAS ™ is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
More
